Johnson & Johnson SPRAVATO — Percent Change (as a percent) increased by 23.8% to 157.5% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from 156.3% to 157.5%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates accelerating market adoption or price realization, whereas a negative percentage suggests slowing demand, competitive pressure, or potential market contraction.
This metric measures the period-over-period growth rate of revenue for a specific pharmaceutical product line. It provid...
Comparable to year-over-year or quarter-over-quarter product growth rates disclosed by peer pharmaceutical firms to track the performance of key growth drivers.
jnj_segment_spravato_percent_change_as_a_percent| Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | 169.3% | 157.2% | 219.8% | 191.6% | 156.3% | 111.9% | 127.2% | 157.5% |
| QoQ Change | — | -7.1% | +39.8% | -12.8% | -18.4% | -28.4% | +13.7% | +23.8% |
| YoY Change | — | — | — | +13.2% | -0.6% | -49.1% | -33.6% | +0.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.